Nuwellis

NUWE

Market cap $3.41M

Overview Fund Activity

3.78 USD

-0.19

4.79%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

3.79

+0.01

0.26%

1 day

-4.79%

5 days

-9.79%

1 month

-40%

3 months

-67.72%

6 months

-91.89%

Year to date

-92.5%

1 year

-92.86%

5 years

-100%

10 years

-100%

About: Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

Employees: 38

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

0.1% more ownership

Funds ownership: 0.08% [Q1] → 0.18% (+0.1%) [Q2]

10% less funds holding

Funds holding: 10 [Q1] → 9 (-1) [Q2]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

44% less capital invested

Capital invested by funds: $129K [Q1] → $72.1K (-$56.5K) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 5 articles about NUWE published over the past 30 days

Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration

EDEN PRAIRIE, Minn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, today announced that the United States Patent and Trademark Office has issued U.S. Patent No.

Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration

Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment

Watch the “What This Means” segment here

Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment

Nuwellis' Vivian Receives $3 Million NIH Grant to Accelerate Pediatric Platform and Strengthen Fluid-Management Portfolio

Awarded grant supports dedicated pediatric continuous renal replacement therapy (CRRT) device in development for patients between 2.5 and 20 kg where therapeutic options are scarce Company working to advance Vivian™ towards an investigational device study to support the path to US regulatory clearance MINNEAPOLIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis Inc. (Nasdaq: NUWE), announced today that the National Institutes of Health (NIH) has awarded an approximately $3 million multi-year grant to its development partner, Koronis Biomedical Technologies Corporation (KBT).

Nuwellis' Vivian Receives $3 Million NIH Grant to Accelerate Pediatric Platform and Strengthen Fluid-Management Portfolio

Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management

MINNEAPOLIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall.

Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management

Nuwellis Receives FDA 510(k) Clearance for New Dual Lumen Extended Length Catheter

MINNEAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC).

Nuwellis Receives FDA 510(k) Clearance for New Dual Lumen Extended Length Catheter

Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company

Proposed acquisition supports strategy to drive technology expansion of fluid management offering to include continuous renal health monitoring technologies supporting the full patient journey, from early risk assessment to targeted fluid removal

Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company

Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

MINNEAPOLIS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date/Time: Thursday, August 21, 2025 at 2:40 PM ET Presenter: John Erb, President and Chief Executive Officer Registration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology.

Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript

Nuwellis, Inc. (NASDAQ:NUWE ) Q2 2025 Earnings Conference Call August 14, 2025 9:00 AM ET Company Participants John L. Erb - CEO, President & Chairman of the Board Leah McMullen - Corporate Participant Robert B.

Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript

Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company dedicated to transforming care for fluid overload patients, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.

Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus

MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced its decision to exit international operations in order to focus exclusively on the U.S. market—where the company is seeing the strongest growth and clinical demand. This strategic realignment supports Nuwellis' core business strategy: investing in the markets driving revenue growth.

Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus

See News Rankings

Charts implemented using Lightweight Charts™